The association between oral contraceptive use and lobular and ductal breast cancer in young women

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 936-941

  Nyante, Sarah J ^a,d   Gammon, Marilie D ^a   Malone, Kathleen E ^b   Daling, Janet R ^b   Brinton, Louise A ^c  

^a IL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Ductal carcinoma; Lobular carcinoma; Oral contraceptives

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNITED STATES; BREAST TUMOR; CARCINOMA IN SITU; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; LUNG CARCINOMA; PAGET NIPPLE DISEASE; PATHOLOGY; RISK FACTOR; TIME;

ADULT; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RISK FACTORS; TIME FACTORS;

EID: 38349053782     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23163     Document Type: Article

References (47)

1. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289: 1421-4.
2. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000;88:2561-9.
3. Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.
4. Benz CC, Clarke CA, Moore DH, II. Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1523-7.
5. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
6. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95:2455-64.
7. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287: 734-41.
8. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289:3254-63.
9. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA, Daling JR. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003;14:225-33.
10. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004;100:2328-37.
11. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
12. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981;43:72-6.
13. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983;2:926-30.
14. Meirik O, Lund E, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet 1986;2:650-4.
15. Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 1989;81:1000-4.
16. Oral contraceptive use and breast cancer risk in young women. UK National Case-Control Study Group. Lancet 1989;1:973-82.
17. Breast cancer and combined oral contraceptives: results from a multi-national study. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Br J Cancer 1990;61:110-19.
18. Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst 1989;81:1313-21.
19. Wang QS, Ross RK, Yu MC, Ning JP, Henderson BE, Kimm HT. A case-control study of breast cancer in Tianjin, China. Cancer Epidemiol Biomarkers Prev 1992;1:435-9.
20. Primic-Zakelj M, Evstifeeva T, Ravnihar B, Boyle P. Breast-cancer risk and oral contraceptive use in Slovenian women aged 25 to 54. Int J Cancer 1995;62:414-20.
21. Rookus MA, van Leeuwen FE. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 1994;344:844-51.
22. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35.
23. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78:161-70.
24. Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 1990;66:2253-63.
25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
26. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003;106:961-4.
27. International Classification of Diseases for Oncology, 2nd edn. Geneva: World Health Organization, 1990.
28. Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract 2000;13:1-10.
29. Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999;8:413-19.
30. Terry MB, Gammon MD, Schoenberg JB, Brinton LA, Arber N, Hibshoosh H. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 2002;11:1100-3.
31. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1998.257.
32. McKnight B, Cook LS, Weiss NS. Logistic regression analysis for more than one characteristic of exposure. Am J Epidemiol 1999;149: 984-92.
33. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-14.
34. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, Speizer FE. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 1997;8:65-72.
35. McCredie MR, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control 1998;9:189-98.
36. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:1128-35.
37. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001;93:1811-17.
38. Claus EB, Stowe M, Carter D. Oral contraceptives and the risk of ductal breast carcinoma in situ. Breast Cancer Res Treat 2003;81:129-36.
39. Gill JK, Press MF, Patel AV, Bernstein L. Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 2006;17:1155-62.
40. Rothman KJ, Greenland S. Modern epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1998.123-5.
41. Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 1998;27:1033-7.
42. Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ, Speizer FE, Willett WC. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-8.
43. Nischan P, Ebeling K, Thomas DB, Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 1993;138: 697-703.
44. Coulter A, Vessey M, McPherson K, Crossley B. The ability of women to recall their oral contraceptive histories. Contraception 1986;33:127-37.
45. Wells WA, Carney PA, Eliassen MS, Tosteson AN, Greenberg ER. Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst 1998;90:142-5.
46. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Eusebi V, De Miguel C, Dervan P, et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 1999;434:3-10.
47. Palli D, Galli M, Bianchi S, Bussolati G, Di Palma S, Eusebi V, Gambacorta M, Rosselli Del Turco M. Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy. Eur J Cancer 1996;32A:603-7.